RHYTHM PHARMACEUTICALS, INC. 8-K

What Happened

• Rhythm Pharmaceuticals, Inc. announced on March 19, 2026 that the U.S. Food and Drug Administration approved an expanded indication for IMCIVREE® (setmelanotide) to treat patients living with acquired hypothalamic obesity (HO). The company released a press release and published a presentation describing the approval and filed a Current Report on Form 8-K on March 20, 2026. The 8-K was signed by CFO Hunter Smith.

Key Details

• Announcement date: March 19, 2026; Form 8-K filed March 20, 2026.
• Product: IMCIVREE® (active ingredient setmelanotide) — label expanded to include acquired hypothalamic obesity.
• Company materials: Press release and investor presentation published and furnished as Exhibits 99.1 and 99.2; presentation available at ir.rhythmtx.com.
• The 8-K reports Regulation FD disclosure and an Other Events notice (no financial results or guidance included in this filing).

Why It Matters

• An FDA label expansion formally broadens the approved use of Rhythm’s marketed therapy, potentially increasing the number of patients eligible for treatment and the product’s commercial opportunity.
• For investors, this is a regulatory milestone that can affect Rhythm’s growth prospects and commercial strategy; the company has provided a press release and presentation for more detail, but the 8-K itself does not include updated financials or guidance.